Quercetin — Research Profile

Dasatinib (a leukemia drug) + quercetin (D+Q) was the first senolytic combination tested in humans by James Kirkland at the Mayo Clinic. The protocol typically uses intermittent dosing (3 days on, weeks off) to clear senescent cells. Dasatinib requires a prescription. The quercetin component alone has milder senolytic activity — some people combine quercetin with fisetin as a non-prescription senolytic stack.

Quercetin phytosome (such as Quercefit) is strongly preferred ^[4]. Standard quercetin has only 1-2% bioavailability, meaning most of the dose never reaches your bloodstream. Phytosome formulations complexed with sunflower lecithin improve absorption by up to 20-fold. Bromelain co-administration is a budget-friendly alternative that modestly improves absorption.

Yes. Quercetin stabilizes mast cells and inhibits histamine release, functioning as a natural antihistamine. It is most effective when taken preventively before allergy season begins, as it takes 2-4 weeks to build up anti-allergic effects. It is not a replacement for acute allergy medications but can reduce symptom severity with consistent use.

Bioavailability differs enormously by form. In the human bioavailability review, the aglycone was lowest; a lecithin phytosome (Quercefit) reached about a 20-fold increase and a self-emulsifying formulation up to a 62-fold increase, while glucoside forms absorbed far better than the rutinoside ^[4]. An enhanced-delivery form therefore supplies more active quercetin per milligram than standard powder.

The most consistent human evidence is for modest cardiovascular and anti-inflammatory effects: a meta-analysis of 587 patients found systolic blood pressure fell 3.04 mmHg and diastolic 2.63 mmHg, with larger reductions at 500 mg/day or more ^[2], and a separate meta-analysis found C-reactive protein fell 0.33 mg/L, again mainly at 500 mg/day or more ^[3]. Its senolytic use is still early-stage: a 14-patient, uncontrolled IPF pilot combining quercetin with dasatinib improved walking distance ^[1]. Broader claims (allergy relief, longevity, PCOS) rest largely on animal or preclinical data.

Human trials most often use 500-1000 mg/day, frequently split as 500 mg twice daily (RxList). The measurable blood-pressure and CRP benefits were concentrated in trials dosing at least 500 mg/day ^[2][3]. No single optimal dose is established, and higher intake is not proven to work better.

Time of day has not been directly tested, so morning versus evening is unlikely to matter. What does matter is taking it with a meal containing some fat and fibre, which roughly doubles absorption of standard forms ^[4]. Splitting a higher daily dose into two servings also mirrors how most trials dosed it.

Adverse effects from oral quercetin are rarely reported and generally mild (Andres 2018). The most commonly listed effects are headache and tingling of the arms and legs (RxList). Kidney safety is the main caution: quercetin may enhance nephrotoxic effects in a kidney that is already damaged, and very high oral doses have been flagged as a potential kidney risk (Andres 2018; RxList). At the up-to-1000 mg/day doses used in most trials, adverse effects were uncommon and mild (Andres 2018).

Yes. Quercetin inhibits CYP3A4 and P-glycoprotein, so it can raise blood levels of cyclosporine and may increase warfarin's blood-thinning effect (RxList). It may also reduce the effectiveness of quinolone antibiotics such as ciprofloxacin and levofloxacin, which should be spaced apart from quercetin, and it can add to the effect of blood-pressure medications (RxList).

Adults with mild hypertension or low-grade inflammation have the most direct human evidence for a modest benefit ^[2][3]. It is a poor choice during pregnancy or breastfeeding, where safety data are lacking, and for anyone taking cyclosporine, warfarin, or quinolone antibiotics because of interaction risk (RxList).

There is no established onset, and effects build over weeks rather than appearing acutely. The blood-pressure and CRP reductions reported in trials came from weeks of daily dosing at 500 mg/day or more, not from single doses ^[2][3]. Reassess after roughly 4-12 weeks rather than looking for a same-day change.

Human trials have used up to 500 mg twice daily for 12 weeks without serious adverse events, so intake over that horizon appears reasonably safe (RxList). However, adequate data on continuous use beyond 12 weeks at high doses (1000 mg/day or more) are not available, so open-ended long-term high-dose use is not well characterized (Andres 2018). Lower daily amounts have a longer track record than gram-level doses.

There is no official tolerable upper limit for quercetin. Human trials have generally used up to about 1000 mg/day, with adverse effects rarely reported and mild in nature (Andres 2018). Reported side effects include headache and tingling of the arms and legs, and safety data for continuous high-dose use beyond 12 weeks are not available (RxList; Andres 2018). People with existing kidney damage should be especially cautious, since quercetin may enhance nephrotoxic effects in an already-compromised kidney (Andres 2018).

It is commonly sold alongside vitamin C or bromelain, but there is no human-trial evidence that these pairings improve quercetin's effects. Absorption itself improves roughly two-fold when quercetin is taken with dietary fat and fibre ^[4]. Note that the senolytic protocol pairing quercetin with dasatinib uses a prescription drug on an intermittent medical schedule and is an experimental regimen, not a self-directed supplement stack ^[1].

Plain quercetin (aglycone or dihydrate) is absorbed poorly, so the delivery form matters more than the raw milligram count. Enhanced forms such as a lecithin phytosome (Quercefit) have shown roughly 20-fold higher bioavailability than aglycone in human pharmacokinetic studies ^[4]. Check that the label states the specific form and the actual quercetin dose rather than hiding it in a proprietary blend.